Frank Zenke

Company: Merck KGaA

Job title: Global Head DNA Damage Response Research

Seminars:

Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy? 2:20 pm

Analyzing the current applications of these inhibitors both in preclinical and clinical studies either as single agents or in combinations with chemotherapy, radiotherapy and immunotherapy Dissecting toxicity profiles (bone marrow toxicity?) Opening the ATR inhibitor black box: what clinical space will they occupy? Understanding biomarker indications for ATR sensitivity: Cyclin E, ATM Loss? not as…Read more

day: Day One

Preclinical & Clinical Exploration of ATR Inhibitors 10:00 am

Preclinical pharmacology profile of Merck ATR inhibitors (Berzosertib, M1774) Preclinical exploration of options for mono- and combination therapy Directions of clinical development for ATR inhibitorsRead more

day: Day One